# US 8,277,842 B1 · Enteric-coated HT-2157 compositions and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,842 B1
- Document ID: US8277842B1
- Status: Granted
- Kind: B1
- Application number: 13/354,428
- Filed: 2012-01-20
- Granted: 2012-10-02
- Earliest claimed: 2012-01-20
- Assignees: Dart NeuroScience (Cayman) Ltd.
- Inventors: Alan P Kaplan
- Web page: https://patentgrep.com/patent/US8277842B1

## CPC

- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Drug compositions comprising the compound HT-2157 and their therapeutic uses, including the treatment of CNS disorders and cognitive impairments and the modulation of cognitive function, are disclosed. More particularly, the present invention relates to enteric-coated formulations comprising HT-2157 that reduce the appearance of clinically relevant methemoglobinemia relative to administration of non-enteric-coated formulations comprising HT-2157.

## Claims

### Claim 1

A composition comprising a solid-dosage form, wherein said solid-dosage form comprises:
(a) a therapeutically effective amount of HT-2157 effective for the treatment of a cognitive or nervous system disorder, disease, or condition in a subject, which has the following structure:
(b) an enteric coating.

### Claim 2 (depends on 1)

The composition of claim 1,
wherein administration of the enteric-coated composition to said subject reduces appearance of clinically relevant methemoglobinemia, relative to administration of a non-enteric coated composition comprising the same amount of HT-2157.

### Claim 3 (depends on 1)

The composition of claim 1,
wherein administration of the enteric-coated composition to said subject results in a lower increase in percent of methemoglobin, relative to administration of a non-enteric coated composition comprising the same amount of HT-2157.

### Claim 4 (depends on 3)

The composition of claim 3,
wherein said administration of the enteric-coated composition increases methemoglobin levels to less than about 3 percent.

### Claim 5 (depends on 3)

The composition of claim 3,
wherein said administration of the enteric-coated composition increases methemoglobin levels to less than about 1.5 percent.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the enteric coating comprises a methacrylic polymer.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising one or more excipients selected from the following: a diluent, a binder, a surfactant, a glidant, and a lubricant.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the composition remains stable after about 1 year of storage at 25° C./60% RH or after about 6 months of storage at 40° C./75% RH.

### Claim 9

A method of reducing the appearance of clinically relevant methemoglobinemia in a subject, relative to administration of a non-enteric coated composition comprising the same amount of HT-2157, comprising administering to said subject a composition comprising a solid-dosage form, wherein said solid-dosage form comprises:
(a) a therapeutically effective amount of HT-2157 effective for the treatment of a cognitive or nervous system disorder, disease, or condition in said subject, which has the following structure:
(b) an enteric coating.

### Claim 10

A method comprising:
administering a composition comprising a solid-dosage form to a subject, wherein said solid-dosage form comprises:
(a) a therapeutically effective amount of HT-2157 effective for the treatment of a cognitive or nervous system disorder, disease, or condition in said subject, which has the following structure:
(b) an enteric coating,
wherein said administering results in a lower increase in percent of methemoglobin, relative to administration of a non-enteric coated composition comprising the same amount of HT-2157.

### Claim 11 (depends on 10)

The method of claim 10,
wherein said administration of the enteric coated composition increases methemoglobin levels to less than about 3 percent.

### Claim 12 (depends on 10)

The method of claim 10,
wherein said administration of the enteric coated composition increases methemoglobin levels to less than about 1.5 percent.

### Claim 13 (depends on 9)

The method of claim 9,
wherein the enteric coating of the composition administered in step (a) comprises a methacrylic polymer.

### Claim 14 (depends on 9)

The method of claim 9,
wherein the composition administered in step (a) further comprises one or more excipients selected from the following: a diluent, a binder, a surfactant, a glidant, and a lubricant.

### Claim 15 (depends on 9)

The method of claim 9, wherein the composition administered in step (a) remains stable after about 1 year of storage at 25° C./60% R.H or after about 6 months of storage at 40° C./75% R.H.

### Claim 16 (depends on 1)

A method of treating a CNS disorder comprising administering the composition of claim 1 to a subject in need thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the CNS disorder is depression or anxiety.

### Claim 18 (depends on 1)

A method comprising the steps of:
(a) providing cognitive training to an animal in need of treatment of a cognitive impairment under conditions sufficient to produce an improvement in performance by said animal of a cognitive function whose deficit is associated with said cognitive impairment;
(b) administering the composition of claim 1 to said animal in conjunction with said cognitive training;
(c) repeating said providing and said administering of steps (a) and (b) one or more times; and
(d) reducing the number of training sessions sufficient to produce said improvement in performance, relative to the improvement in performance produced by cognitive training alone.

### Claim 19 (depends on 18)

The method of claim 18, wherein said administering reduces appearance of clinically relevant methemoglobinemia or results in a lower increase in percent of methemoglobin, relative to administration of a non-enteric coated composition comprising the same amount of HT-2157.

### Claim 20 (depends on 18)

The method of claim 18, wherein the cognitive impairment includes a memory impairment.
